menu

Hemophilia B Treatment Market

Schedule Call

Hemophilia B Treatment Market

Hemophilia B Treatment Market by Treatment (Recombinant Factor IX Therapy, Gene Therapy, Others), Disease Management (On Demand, Prophylaxis), End-user (Hospitals, Specialty Clinics, Homecare) – Global Outlook & Forecast 2022-2030

GR - 364230 Category: Pharmaceuticals

Number of pages: 100  |  Report Format: PDF  |  Published date: 17 February, 2023

Historical Years – 2020  |  Base Year – 2021  |  Forecasted Years – 2022-2030


Hemophilia B Treatment Market Scope

Report Attribute

Details

Market size value in 2021

US$ 1.5 billion

Revenue forecast in 2030

US$ 3 billion

Growth Rate

CAGR of 8.8% from 2022 to 2030

Base year for estimation

2021

Forecast period

2022-2030

Historical Year

2020

Segments covered

Treatment, Disease Management, End-user, and Region.

Regional scope

North America, Europe, Asia Pacific, and the Rest of the World (ROW)

Report Overview

According to the deep-dive market assessment study by Growth Plus Reports, the global hemophilia B treatment market was valued at US$ 1.5 billion in 2021 and is expected to register a revenue CAGR of 8.8% to reach US$ 3 billion by 2030.

Market Fundamentals

Hemophilia B is a rare disease in which the blood does not clot normally due to a lack of blood-clotting proteins (clotting factors). Hemophilia B patients may bleed more profusely and for a longer period. Hemophilia B, in its severe stage, can cause internal bleeding, particularly in the knees, ankles, and elbows. Internal bleeding poses a life-threatening risk and can harm tissues and organs.

Hemophilia B is a coagulation factor deficit caused by low or absent levels of factor IX (FIX). The symptoms of recurrent prolonged bleeding are caused by inadequate or absent plasma FIX levels, which cleave and activate FIX within the coagulation cascade. FIX is a plasma protease that functions in the intrinsic blood coagulation pathway and depends on vitamin K. 

Symptoms of hemophilia B vary widely from patient to patient. The severity of hemophilia B can range from mild to severe. Individuals with mild hemophilia have factor IX levels that range between 5 and 40% of normal; those with moderate hemophilia have factor levels that range between 1 and 5% of normal; and those with severe hemophilia have factor levels that fall below 1% of normal. 

Individuals suffering from moderate to severe hemophilia undergo spontaneous bleeding into any organ, including the kidneys, stomach, intestines, and brain. Bleeding within the kidneys, stomach, and intestines can result in hematuria, melena, or hematochezia. This bleeding can reach the brain and induce headaches, stiff neck, vomiting, seizures, and mental status abnormalities such as excessive drowsiness, poor arousal levels, and even death.

[67667577]

Market Dynamics

Increasing incidences of hemophilia B is the key factor influencing the global hemophilia B treatment market. A spontaneous mutation brings on about one-third of instances.  The US Centers for Disease Control and Prevention (CDC) estimate that 1 in 5,000 live births will result in hemophilia in 2022. In the U.S., there are between 30,000 and 33,000 hemophiliacs. All people and ethnic groupings are affected. Hemophilia B affects four times less common than hemophilia A. The disease is more common in males than in women. According to the National Center of Biotechnology and Information (NCBI) estimates in 2022, hemophilia B affects 1 in 40,000 males, which is almost 15% of all hemophilia cases. All ethnic groups are equally distributed among them. Due to a higher prevalence of consanguineous marriages, certain cultures, such as Egyptians and Ashkenazi Jews, have higher disease incidences. 

Increased drug approvals for treating hemophilia B is another factor growing the global hemophilia B treatment market. For instance, in November 2022, the Food and Drug Administration (FDA) authorized Hemgenix (etranacogene dezaparvovec), an adeno-associated virus vector-based gene therapy. The drug is indicated for treating people with Hemophilia B, receiving Factor IX prophylactic medication, having a current or previous life-threatening hemorrhage, or having repeated, major spontaneous bleeding episodes. Similarly, Shanghai Vitalgen BioPharma Co. Ltd. is researching to evaluate the safety and efficacy of VGB-R04 in adult hemophilia B patients. The growth of the global hemophilia B treatment market can be constrained due to poor healthcare standards and fewer treatment alternatives in low-income regions, such as the Middle East and Africa.

Market Ecosystem

The global hemophilia B treatment market has been analyzed from four perspectives: Treatment, Disease Management, End-user, and Region.

Hemophilia B Treatment Market by Disease Management

[85675556]

Based on disease management, the global hemophilia B treatment market has been segmented into recombinant factor IX therapy, gene therapy, and others.  

The recombinant factor IX therapy segment is currently leading the global hemophilia B treatment market. Recombinant DNA technology is used to create recombinant IX factors. It has structural and functional traits with endogenous factor IX. It shares the main amino acid sequence with the Ala148 allelic variant of human factor IX. This is in contrast to the human Factor IX complex, which is made from human blood. Recombinant Factor IX is recommended for adult and pediatric patients to manage and avoid bleeding.

The gene therapy segment is expected to show high growth in the forecast period. Gene therapy has the potential to heal hemophilia B patients by creating continuous endogenous production of factor IX (FIX) after the transfer of a functioning gene to replace the faulty gene. 

Hemophilia B Treatment Market by Treatment 

Based on treatment types, the global hemophilia B treatment market is segmented into on-demand and prophylaxis.

The most common treatment for hemophilia B is on-demand treatment. This involves treating bleeding as they occur, using either factor IX concentrate or factor IX complex. Factor IX concentrate is a purified form of factor IX. In contrast, the factor IX complex is a mixture of factor IX and factor X, both needed for a normal blood clot. Prophylaxis treatment involves regularly infusing factor IX to prevent bleeding episodes from occurring. Both treatment options have their advantages and disadvantages. The best option for each individual will depend on several factors, including the severity of the condition, the frequency of bleeding episodes, and the individual's personal preferences. 

Hemophilia B Treatment Market by End-user 

Based on end-users, the global hemophilia b treatment market is grouped into hospitals, specialty clinics, and home care. 

The hospital segment has dominated the global hemophilia B treatment market. It is attributed to the increased demand for hospitals due to access to a multidisciplinary team of healthcare providers. In addition, hospitals typically have the necessary resources and equipment to treat hemophilia B, such as on-site infusion centers and specialized clinics. This can be especially beneficial for patients requiring frequent infusions or other treatments, as it can save them the time and inconvenience of traveling to multiple locations for care.

Hemophilia B Treatment Market by Region 

Regionally, the global Hemophilia B Treatment Market has been segmented into North America, Europe, Asia Pacific, and the Rest of The World. 

North America held the majority of revenue share in 2021, attributed to rising awareness about the condition, improved diagnosis and treatment, and the availability of new therapies. Additionally, the rising number of hemophilia B cases in the region has also increased the number of patients seeking treatment, leading to further growth in the market. Furthermore, the availability of cost-effective treatments and the increasing number of collaborations between pharmaceutical companies and research institutions are also driving the North America Hemophilia B treatment market. 

The Asia Pacific region is anticipated to increase with a high CAGR in the forecast years. Market players in coming years will launch many new pipeline drugs for hemophilia B. In addition to the launch of new drugs, increased diagnosis activities are also influencing the global hemophilia B treatment market. Moreover, market players, such as Sun Pharma, Baxalta, and Novo Nordisk, have created awareness of hemophilia B in the region. 

Competitive Landscape

The prominent players operating in the global hemophilia B treatment market are:

Frequently Asked Questions About This Report

The high prevalence of hemophilia B is the key factor increasing the hemophilia B treatment market growth. Moreover, increased approval of new therapies for the treatment and rising diagnosis practices are other factors influencing the market growth.

Some of the prominent players operating in the global hemophilia B treatment market are Aspen Holdings, Baxter, EMERGENT, Mylan N.V., Bristol Myers Squibb Company, GSK Plc., Bayer AG, and others.

High cost of treatments such as gene therapy can restrain the global hemophilia B treatment market. Also, due to low healthcare standards, diagnosis practices and treatment activities are limited in low-income countries like the Middle East and Africa.

The global hemophilia B treatment market is expected to grow at a revenue CAGR of 8.8% during the forecast period from 2022 to 2030.

The recombinant factor IX therapy segment occupies the largest revenue share in the global hemophilia B treatment market.

Table of Content

  1. INTRODUCTION
    1. Market Ecosystem
    2. Timeline Under Consideration
      1. Historical Years – 2020
      2. Base Year – 2021
      3. Forecast Years – 2022 to 2030
    3. Currency Used in the Report
  2. RESEARCH METHODOLOGY 
    1. Research Approach
    2. Data Collection Methodology
    3. Data Sources
      1. Secondary Sources 
      2. Primary Sources
    4. Market Estimation Approach
      1. Bottom Up
      2. Top Down 
    5. Market Forecasting Model
    6. Limitations and Assumptions
  3. PREMIUM INSIGHTS
    1. Current Market Trends (COVID-19 Perspective)
    2. Key Players & Competitive Positioning (2021) 
  4. MARKET DYNAMICS
    1. Drivers
    2. Restraints/Challenges
    3. Opportunities
  5. GLOBAL HEMOPHILIA B TREATMENT MARKET - ANALYSIS & FORECAST, BY TREATMENT   
    1. Recombinant Factor IX Therapy
    2. Gene Therapy
    3. Others
  6. GLOBAL HEMOPHILIA B TREATMENT MARKET - ANALYSIS & FORECAST, BY DISEASE MANAGEMENT 
    1. On Demand 
    2. Prophylaxis 
  7. GLOBAL HEMOPHILIA B TREATMENT MARKET - ANALYSIS & FORECAST, BY END-USER 
    1. Hospitals 
    2. Specialty Clinics 
    3. Homecare 
  8. GLOBAL HEMOPHILIA B TREATMENT MARKET - ANALYSIS & FORECAST, BY REGION
    1. North America Hemophilia B Treatment Market
      1. North America Hemophilia B Treatment Market, by Treatment
      2. North America Hemophilia B Treatment Market, by Disease Management
      3. North America Hemophilia B Treatment Market, by End-user
      4. North America Hemophilia B Treatment Market, by Country
        1. U.S.
          1. U.S. Hemophilia B Treatment Market, by Treatment
          2. U.S. Hemophilia B Treatment Market, by Disease Management
          3. U.S. Hemophilia B Treatment Market, by End-user
        2. Canada
          1. Canada Hemophilia B Treatment Market, by Treatment
          2. Canada Hemophilia B Treatment Market, by Disease Management
          3. Canada Hemophilia B Treatment Market, by End-user
    2. Europe Hemophilia B Treatment Market
      1. Europe Hemophilia B Treatment Market, by Treatment
      2. Europe Hemophilia B Treatment Market, by Disease Management 
      3. Europe Hemophilia B Treatment Market, by End-user
      4. Europe Hemophilia B Treatment Market, by Country/Region
        1. Germany
          1. Germany Hemophilia B Treatment Market, by Treatment
          2. Germany Hemophilia B Treatment Market, by Disease Management
          3. Germany Hemophilia B Treatment Market, by End-user
        2. U.K.
          1. U.K. Hemophilia B Treatment Market, by Treatment
          2. U.K. Hemophilia B Treatment Market, by Disease Management
          3. U.K. Hemophilia B Treatment Market, by End-user
        3. France
          1. France Hemophilia B Treatment Market, by Treatment
          2. France Hemophilia B Treatment Market, by Disease Management
          3. France Hemophilia B Treatment Market, by End-user
        4. Spain
          1. Spain Hemophilia B Treatment Market, by Treatment
          2. Spain Hemophilia B Treatment Market, by Disease Management
          3. Spain Hemophilia B Treatment Market, by End-user
        5. Italy
          1. Italy Hemophilia B Treatment Market, by Treatment
          2. Italy Hemophilia B Treatment Market, by Disease Management 
          3. Italy Hemophilia B Treatment Market, by End-user
        6. Rest of Europe 
          1. Rest of Europe Hemophilia B Treatment Market, by Treatment
          2. Rest of Europe Hemophilia B Treatment Market, by Disease Management 
          3. Rest of Europe Hemophilia B Treatment Market, by End-user
    3. Asia Pacific Hemophilia B Treatment Market
      1. Asia Pacific Hemophilia B Treatment Market, by Treatment
      2. Asia Pacific Hemophilia B Treatment Market, by Disease Management 
      3. Asia Pacific Hemophilia B Treatment Market, by End-user
      4. Asia Pacific Hemophilia B Treatment Market, by Country/Region
        1. China
          1. China Hemophilia B Treatment Market, by Treatment
          2. China Hemophilia B Treatment Market, by Disease Management 
          3. China Hemophilia B Treatment Market, by End-user
        2. Japan
          1. Japan Hemophilia B Treatment Market, by Treatment
          2. Japan Hemophilia B Treatment Market, by Disease Management 
          3. Japan Hemophilia B Treatment Market, by End-user
        3. India
          1. India Hemophilia B Treatment Market, by Treatment
          2. India Hemophilia B Treatment Market, by Disease Management 
          3. India Hemophilia B Treatment Market, by End-user
        4. South Korea
          1. South Korea Hemophilia B Treatment Market, by Treatment
          2. South Korea Hemophilia B Treatment Market, by Disease Management 
          3. South Korea Hemophilia B Treatment Market, by End-user
        5. Australia
          1. Australia Hemophilia B Treatment Market, by Treatment
          2. Australia Hemophilia B Treatment Market, by Disease Management 
          3. Australia Hemophilia B Treatment Market, by End-user
        6. Rest of Asia Pacific
          1. Rest of Asia Pacific Hemophilia B Treatment Market, by Treatment
          2. Rest of Asia Pacific Hemophilia B Treatment Market, by Disease Management 
          3. Rest of Asia Pacific Hemophilia B Treatment Market, by End-user
    4. Rest of the World Hemophilia B Treatment Market
      1. Rest of the World Hemophilia B Treatment Market, by Treatment
      2. Rest of the World Hemophilia B Treatment Market, by Disease Management 
      3. Rest of the World Hemophilia B Treatment Market, by End-user
      4. Rest of the World Hemophilia B Treatment Market, by Region
        1. Latin America
          1. Latin America Hemophilia B Treatment Market, by Treatment
          2. Latin America Hemophilia B Treatment Market, by Disease Management 
          3. Latin America Hemophilia B Treatment Market, by End-user
        2. Middle East & Africa
          1. Middle East & Africa Hemophilia B Treatment Market, by Treatment
          2. Middle East & Africa Hemophilia B Treatment Market, by Disease Management 
          3. Middle East & Africa Hemophilia B Treatment Market, by End-user
  9. COMPANY PROFILE
    1. Aspen Holdings 
      1. Business Snapshot
      2. Disease Management Offered
      3. Financial Details*
      4. Strategic Developments
    2. Emcure Pharmaceuticals 
    3. Baxter 
    4. EMERGENT 
    5. Mylan N.V. 
    6. Bristol Myers Squibb Company 
    7. GSK Plc. 
    8. Bayer AG 
    9. Grifols S.A. 
    10. Hikma Pharmaceuticals Plc 

*Insights on financial performance are subject to the availability of information in the public domain

List of Tables

  1. Global Hemophilia B Treatment Market, by Disease Management, 2020-2030 (US$ Million)
  2. Global Hemophilia B Treatment Market, by Treatment, 2020-2030 (US$ Million)
  3. Global Hemophilia B Treatment Market, by End-user, 2020–2030 (US$ Million) 
  4. Global Hemophilia B Treatment Market, by Region, 2020-2030 (US$ Million) 
  5. North America Hemophilia B Treatment Market, by Treatment, 2020-2030 (US$ Million) 
  6. North America Hemophilia B Treatment Market, by Disease Management, 2020-2030 (US$ Million) 
  7. North America Hemophilia B Treatment Market, by End-user, 2020–2030 (US$ Million)
  8. North America Hemophilia B Treatment Market, by Country, 2020-2030 (US$ Million) 
  9. U.S. Hemophilia B Treatment Market, by Treatment, 2020-2030 (US$ Million) 
  10. U.S. Hemophilia B Treatment Market, by Disease Management, 2020-2030 (US$ Million) 
  11. U.S. Hemophilia B Treatment Market, by End-user, 2020–2030 (US$ Million) 
  12. Canada Hemophilia B Treatment Market, by Treatment, 2020-2030 (US$ Million) 
  13. Canada Hemophilia B Treatment Market, by Disease Management, 2020-2030 (US$ Million) 
  14. Canada Hemophilia B Treatment Market, by End-user, 2020–2030 (US$ Million) 
  15. Europe Hemophilia B Treatment Market, by Treatment, 2020-2030 (US$ Million) 
  16. Europe Hemophilia B Treatment Market, by Disease Management, 2020-2030 (US$ Million)
  17. Europe Hemophilia B Treatment Market, by End-user, 2020–2030 (US$ Million) 
  18. Europe Hemophilia B Treatment Market, By Country/ Region, 2020-2030 (US$ Million) 
  19. Germany Hemophilia B Treatment Market, by Treatment, 2020-2030 (US$ Million) 
  20. Germany Hemophilia B Treatment Market, by Disease Management, 2020-2030 (US$ Million) 
  21. Germany Hemophilia B Treatment Market, by End-user, 2020–2030 (US$ Million) 
  22. U.K. Hemophilia B Treatment Market, by Treatment, 2020-2030 (US$ Million) 
  23. U.K. Hemophilia B Treatment Market, by Disease Management, 2020-2030 (US$ Million) 
  24. U.K. Hemophilia B Treatment Market, by End-user, 2020–2030 (US$ Million) 
  25. France Hemophilia B Treatment Market, by Treatment, 2020-2030 (US$ Million) 
  26. France Hemophilia B Treatment Market, by Disease Management Treatment , 2020-2030 (US$ Million) 
  27. France Hemophilia B Treatment Market, by End-user, 2020–2030 (US$ Million) 
  28. Italy Hemophilia B Treatment Market, by Treatment, 2020-2030 (US$ Million) 
  29. Italy Hemophilia B Treatment Market, by Disease Management, 2020-2030 (US$ Million) 
  30. Italy Hemophilia B Treatment Market, by End-user, 2020–2030 (US$ Million) 
  31. Spain Hemophilia B Treatment Market, by Treatment, 2020-2030 (US$ Million) 
  32. Spain Hemophilia B Treatment Market, by Disease Management, 2020-2030 (US$ Million)
  33. Spain Hemophilia B Treatment Market, by End-user, 2020–2030 (US$ Million) 
  34. Rest of Europe Hemophilia B Treatment Market, by Treatment, 2020-2030 (US$ Million) 
  35. Rest of Europe Hemophilia B Treatment Market, by Disease Management, 2020-2030 (US$ Million) 
  36. Rest of Europe Hemophilia B Treatment Market, by End-user, 2020–2030 (US$ Million) 
  37. Asia Pacific Hemophilia B Treatment Market, by Treatment, 2020-2030 (US$ Million) 
  38. Asia Pacific Hemophilia B Treatment Market, by Disease Management, 2020-2030 (US$ Million) 
  39. Asia Pacific Hemophilia B Treatment Market, by End-user, 2020–2030 (US$ Million) 
  40. Asia Pacific Hemophilia B Treatment Market, by Country/ Region, 2020-2030 (US$ Million) 
  41. China Hemophilia B Treatment Market, by Treatment, 2020-2030 (US$ Million) 
  42. China Hemophilia B Treatment Market, by Disease Management, 2020-2030 (US$ Million) 
  43. China Hemophilia B Treatment Market, by End-user, 2020–2030 (US$ Million) 
  44. Japan Hemophilia B Treatment Market, by Treatment, 2020-2030 (US$ Million) 
  45. Japan Hemophilia B Treatment Market, by Disease Management, 2020-2030 (US$ Million) 
  46. Japan Hemophilia B Treatment Market, by End-user, 2020–2030 (US$ Million) 
  47. India Hemophilia B Treatment Market, by Treatment, 2020-2030 (US$ Million) 
  48. India Hemophilia B Treatment Market, by Disease Management, 2020-2030 (US$ Million) 
  49. India Hemophilia B Treatment Market, by End-user, 2020–2030 (US$ Million) 
  50. South Korea Hemophilia B Treatment Market, by Treatment, 2020-2030 (US$ Million) 
  51. South Korea Hemophilia B Treatment Market, by Disease Management, 2020-2030 (US$ Million) 
  52. South Korea Hemophilia B Treatment Market, by End-user, 2020–2030 (US$ Million) 
  53. Australia Hemophilia B Treatment Market, by Treatment, 2020-2030 (US$ Million) 
  54. Australia Hemophilia B Treatment Market, by Disease Management, 2020-2030 (US$ Million) 
  55. Australia Hemophilia B Treatment Market, by End-user, 2020–2030 (US$ Million) 
  56. Rest of Asia Pacific Hemophilia B Treatment Market, by Treatment, 2020-2030 (US$ Million) 
  57. Rest of Asia Pacific Hemophilia B Treatment Market, by Disease Management, 2020-2030 (US$ Million) 
  58. Rest of Asia Pacific Hemophilia B Treatment Market, by End-user, 2020–2030 (US$ Million) 
  59. Rest of the World Hemophilia B Treatment Market, by Treatment, 2020-2030 (US$ Million) 
  60. Rest of the World Hemophilia B Treatment Market, by Disease Management, 2020-2030 (US$ Million) 
  61. Rest of the World Hemophilia B Treatment Market, by End-user, 2020–2030 (US$ Million) 
  62. Rest of the World Hemophilia B Treatment Market, by Region, 2020-2030 (US$ Million) 
  63. Latin America Hemophilia B Treatment Market, by Treatment, 2020-2030 (US$ Million) 
  64. Latin America Hemophilia B Treatment Market, by Disease Management, 2020-2030 (US$ Million) 
  65. Latin America Hemophilia B Treatment Market, by End-user, 2020–2030 (US$ Million) 
  66. Middle East and Africa Hemophilia B Treatment Market, by Treatment, 2020-2030 (US$ Million) 
  67. Middle East and Africa Hemophilia B Treatment Market, by Disease Management, 2020-2030 (US$ Million) 
  68. Middle East and Africa Hemophilia B Treatment Market, by End-user, 2020–2030 (US$ Million) 

List of Figures

  1. Hemophilia B Treatment Market Ecosystem  
  2. Snapshot of Global Hemophilia B Treatment Market, 2020-2030 
  3. Snapshot of Global Hemophilia B Treatment Market, By Region, 2020-2030 
  4. Global Hemophilia B Treatment Market: COVID-19 Pandemic Impact Assessment 
  5. Global Hemophilia B Treatment Market: Key Players & Competitive Positioning (2021) 
  6. Pharmaceutical Filtration: Market Dynamics 
  7. Global Hemophilia B Treatment Market by Recombinant IX Factor Therapy, 2020-2030 (US$ Million) 
  8. Global Hemophilia B Treatment Market by Gene Therapy, 2020-2030 (US$ Million)
  9. Global Hemophilia B Treatment Market by Other Disease Management, 2020-2030 (US$ Million) 
  10. Global Hemophilia B Treatment Market by On Demand Treatment, 2020-2030 (US$ Million) 
  11. Global Hemophilia B Treatment Market by Prophylaxis Treatment, 2020-2030 (US$ Million) 
  12. Global Hemophilia B Treatment Market by Hospitals, 2020-2030 (US$ Million) 
  13. Global Hemophilia B Treatment Market by Specialty Clinics, 2020-2030 (US$ Million) 
  14. Global Hemophilia B Treatment Market by Homecare, 2020-2030 (US$ Million) 
  15. North America Hemophilia B Treatment Market, 2020-2030 (US$ Million) 
  16. U.S. Hemophilia B Treatment Market, 2020-2030 (US$ Million) 
  17. Canada Hemophilia B Treatment Market, 2020-2030 (US$ Million) 
  18. Europe Hemophilia B Treatment Market, 2020-2030 (US$ Million) 
  19. Germany Hemophilia B Treatment Market, 2020-2030 (US$ Million) 
  20. U.K. Hemophilia B Treatment Market, 2020-2030 (US$ Million) 
  21. France Hemophilia B Treatment Market, 2020-2030 (US$ Million) 
  22. Italy Hemophilia B Treatment Market, 2020-2030 (US$ Million) 
  23. Spain Hemophilia B Treatment Market, 2020-2030 (US$ Million) 
  24. Rest of Europe Hemophilia B Treatment Market, 2020-2030 (US$ Million) 
  25. Asia Pacific Hemophilia B Treatment Market, 2020-2030 (US$ Million) 
  26. China Hemophilia B Treatment Market, 2020-2030 (US$ Million) 
  27. Japan Hemophilia B Treatment Market, 2020-2030 (US$ Million) 
  28. India Hemophilia B Treatment Market, 2020-2030 (US$ Million) 
  29. South Korea Hemophilia B Treatment Market, 2020-2030 (US$ Million) 
  30. Australia Hemophilia B Treatment Market, 2020-2030 (US$ Million) 
  31. Rest of Asia Pacific Hemophilia B Treatment Market, 2020-2030 (US$ Million) 
  32. Rest of the World Hemophilia B Treatment Market, 2020-2030 (US$ Million) 
  33. Latin America Hemophilia B Treatment Market, 2020-2030 (US$ Million) 
  34. Middle East & Africa Hemophilia B Treatment Market, 2020-2030 (US$ Million)
  35. Aspen Holdings (South Africa) Revenue from 2018-2021 (US$ Million)
  36. Emcure Pharmaceuticals (India) Revenue from 2018-2021 (US$ Million)
  37. Baxter (U.S.) Revenue from 2018-2021 (US$ Million)
  38. EMERGENT (U.S.) Revenue from 2018-2021 (US$ Million)
  39. Mylan N.V. (U.S.) Revenue from 2018-2021 (US$ Million)
  40. Bristol Myers Squibb Company (U.S.) Revenue from 2018-2021 (US$ Million)
  41. GSK Plc. (U.K) Revenue from 2018-2021 (US$ Million)
  42. Bayer AG (Germany) Revenue from 2018-2021 (US$ Million)
  43. Grifols S.A. (Spain) Revenue from 2018-2021 (US$ Million)
  44. Hikma Pharmaceuticals Plc (Japan) Revenue from 2018-2021 (US$ Million)

Single User License
Single User License
Multi User License
Enterprise User License
$4,750.00
Provides access to one user only and should not be shared with other employees within the organization.
Provides access to up to five users within the department or an organization.
Provides access to all the employees in the organization. The report can also be shared with subsidiaries, sister concerns and group entities.
Grants user/users’ access to quantitative data only, which includes but is not restricted to numeric data, tables, and charts as defined by Growth+ Reports.

Using the fundamental research and knowledge services capabilities of GRG Health, Growth Plus Reports may now be tailored based on client needs.

GRG Health's unique GrowthMIX strategy and comprehensive research methodology enable us to provide unique and valuable insights to our clients while uncovering trends that would not be discovered using traditional techniques.

sans

Snehal Deshmukh

Principle Consultant

Speak to analyst